Latest Headlines

Latest Headlines

Teva's 2nd-gen Copaxone makes the grade

No question about it, Copaxone is still Teva Pharmaceutical Industries' ($TEVA) leading drug. And Teva wants to keep sales up--and not just until generic competition arrives in 2015. That's why it's been investing so heavily in developing a new, less-frequent dosing schedule. If the new, higher-dose Copaxone version can grab a foothold, then Teva stands to keep more of the multibillion-dollar drug's share of the MS market.

Sanofi's Genzyme hits main target in PhIII study of rare disease drug

The Cambridge, MA-based unit of the French drug giant turned in upbeat data from the first Phase III study of the closely watched eliglustat tartrate, an oral drug for the rare genetic disorder that is typically treated with infusions of enzyme therapies.

Transgenic corn yields biotech drug for rare disease

Many biologics are notoriously expensive to produce, but genetically modified corn offers a potential alternative for producing complex protein drugs. And veteran Reuters scribe Ben Hirschler has chronicled one of the latest feats in "molecular farming," with scientists growing an enzyme drug for a rare genetic disease in transgenic corn.

Sanofi workers plan protests as execs prep for big job cuts next week

Neither strike threats nor angry government ministers have stopped Sanofi from pushing ahead with deep job cuts in France. The French newspaper Le Figaro reports that the pharma giant will unveil a cutback of 1,500 to 2,500 jobs on September 25.

D-Day for Sanofi MS drug Aubagio as deep R&D cuts loom

This is a big day for Sanofi and Genzyme, its biologics arm in Boston. The FDA is slated to make a final ruling on Aubagio (teriflunomide), its new oral treatment for multiple sclerosis.

Sanofi plans to buy back $152M in Genzyme CVRs

The move is seen as a sign that Sanofi is confident that the multiple sclerosis drug Lemtrada will be as lucrative as hoped.

Sanofi recalls 9 lots of Genzyme transplant drug

Genzyme is pulling 9 lots of its kidney transplant drug Thymoglobulin after one lot failed a stability test. The company, which is Sanofi's ($SNY) U.S.-based rare disease division, pulled all lots made with raw material suspected to be the "root cause" of the potential shelf-life issue.

Sanofi's Genzyme recalls transplant drug after stability test failure

Sanofi ($SNY) is reporting another manufacturing problem, this time at one of the plants operated by its Genzyme subsidiary, causing it to recall a transplant-rejection drug.

Sanofi hits a speed bump on blockbuster Lemtrada application

Just weeks after Genzyme filed its application for Lemtrada as a new treatment for multiple sclerosis, regulators have handed the NDA back, telling the biologics arm of Sanofi that it needs to complete a rewrite before they can properly assess it.

Sanofi pulls Campath to clear way for higher-priced Lemtrada

The speculation about Genzyme's Campath is over. The company, now a unit of Sanofi, is pulling the plug. Why? To prepare the way for Lemtrada, a multiple sclerosis treatment that is, essentially, Campath by another name.